Zusammenfassung
Durch die Erforschung der Signalwege von B‑Lymphozyten und die Identifizierung von beteiligten Kinasen konnten viele neue, zielgerichtete Therapien entwickelt werden. Am weitesten und besten erforscht sind die Kinaseinhibitoren Ibrutinib und Idelalisib sowie der BCL2-Inhibitor Venetoclax. Zahlreiche prognostische und prädiktive Biomarker stehen zur Verfügung. Die Auswahl der Erstlinientherapie orientiert sich am TP53-Status, dem IGHV-Status und der Patientenfitness. Aktuelle klinische Daten unterstreichen die gute Wirksamkeit der neuen Substanzen sowohl in der Rezidiv- als auch in der Erstlinientherapie. Erworbene Bruton-Tyrosinkinase(BTK)-Resistenzen, medikamentenspezifische Nebenwirkungen und mangelnde Patienten-Compliance sind klinisch ein zunehmendes Problem der neuen Substanzen. Zudem gibt es nur wenige Daten zu Langzeittoxizitäten. Patienten sollten deswegen, wenn immer es geht, innerhalb klinischer Studien behandelt werden. In diesem Übersichtsartikel sollen auf die neuesten Entwicklungen der Diagnostik und Therapie der chronischen lymphatischen Leukämie (CLL) eingegangen und die wichtigsten Aspekte für die Praxis heraus gearbeitet werden.
Abstract
Due to an increasing molecular understanding of the signal pathways of B‑lymphocytes and identification of the kinases involved, many new targeted treatments could be developed. The most and best researched are the kinase inhibitors ibrutinib and idelalisib as well as the BCL2 inhibitor venetoclax. A variety of prognostic and predictive biomarkers have been identified. Currently the selection of first-line treatment is oriented to the TP53 status, immunoglobulin heavy chain gene (IGHV) mutational status and patient fitness. Recent clinical studies underline the effectiveness of the novel substances as first-line treatment and in recurrence situations. Acquired Bruton tyrosine kinase (BTK) resistance, medication-specific side effects and a lack of patient compliance are an increasing clinical problem of the new substances. Additionally, little is known about the long-term toxicity. Therefore, patients should be treated within clinical trials whenever possible. This review article summarizes the most recent developments in the diagnostics and treatment of chronic lymphocytic leukemia (CLL) and the most important aspects for the practice are worked out.
Literatur
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745–2760
The International CLL-IPI working group (2016) An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17(6):779–790
Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J et al (2018) Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase‑3 trials. Leuk Lymphoma. https://doi.org/10.1080/10428194.2018.1540782
Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M et al (2016) Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127(17):2122–2130
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J et al (2016) A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 30(4):929–936
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174
Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P et al (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208–215
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W et al (2016) Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303–309
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942
Shanafelt TD, Wang V, Kay NE, Hanson CA, O’Brien SM, Barrientos JC et al (2018) A randomized phase III study of Ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood 132(Suppl 1):LBA‑4
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W et al (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379(26):2517–2528
Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V et al (2017) Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 129(18):2581–2584
O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C et al (2016) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):109–1418
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110
Goede V (2018) Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of THE CLL11 study. EHA Learning Center, S 215923
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al (2019) Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(1):43–56
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M et al (2019) Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 380(23):2225–2236
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213–223
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S et al (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17(2):200–211
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A et al (2018) Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. https://doi.org/10.1038/s41375-018-0276-9
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S et al (2018) Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107–1120
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C et al (2018) Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. https://doi.org/10.1200/jco.18.01580
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
P. Langerbeins: Research & travel support by Janssen. Honoraria by Janssen, Abbvie. Advisory Board: Sunesis, Janssen. B. Eichhorst: Research support: Roche, Janssen, Abbvie, Gilead. Advisory Board: Janssen, Gilead, Roche, Abbvie, Novartis, Celgene. Honoraria: Roche, Novartis, Gilead, Janssen, Abbvie, Celgene. M. Hallek: Research support for Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Abbvie. Speakers bureau and Advisory Board: Roche Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Boehringer.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Langerbeins, P., Eichhorst, B. & Hallek, M. Aktuelle Therapiestrategien zur chronischen lymphatischen Leukämie. Onkologe 25, 1004–1008 (2019). https://doi.org/10.1007/s00761-019-00655-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-019-00655-y